Yunfu Chen
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
Journal: Emerging microbes & infections
Published: July 10, 2026
Class I capsid assembly modulators induce potent anti-HBV activity through direct viral suppression, innate immune activation and caspase-3-independent clearance of infected hepatocytes.
Journal: Antiviral research
Published: February 24, 2026
Design and biochemical evaluation of 2-cyclopropyl-thioureidobenzamide (CP-TBA) derivatives as potent HBV capsid assembly modulators targeting a novel binding site.
Journal: European journal of medicinal chemistry
Published: February 01, 2025
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial.
Journal: The Journal of infection
Published: November 10, 2024
A hepatitis B virus-free cccDNA-producing stable cell for antiviral screening.
Journal: Antiviral research
Published: November 04, 2024
Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 25, 2024
Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators.
Journal: Bioorganic & medicinal chemistry letters
Published: July 15, 2024
Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives as HBV Capsid Assembly Modulators.
Journal: Journal of medicinal chemistry
Published: October 15, 2023
Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 29, 2019
3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
Journal: Journal of medicinal chemistry
Published: January 31, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026